Trial Profile
CRUKE/08/039: VOICE - A two stage randomised phase I/II open-labelled study to determine the efficacy of VOrInostat given with Cisplatinum + Etoposide in previously untreated extensive stage SCLC patients
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Apr 2010
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Etoposide (Primary) ; Vorinostat (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms VOICE
- 14 May 2009 New trial record